If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email firstname.lastname@example.org
Photodynamic therapy (PDT) has been designated as a "promising new modality in the treatment of cancer" since the early 1980s. Light must be delivered in order to activate photodynamic therapy. Most photosensitizers have strong absorption in the ultraviolet (UV)-blue range, therefore, UV-blue light is needed for their activation. Unfortunately, UV-blue light has minimal penetration into tissue and its application for in vivo activation is a problem. To solve the problem and enhance the PDT treatment for deep cancers, we introduce new PDT systems in which the light is generated by afterglow nanoparticles with attached photosensitizers. When the nanoparticle-photosensitizer conjugates are targeted to tumor, the light from afterglow nanoparticles will activate the photosensitizers for photodynamic therapy. Therefore, no external light is required for treatment. More importantly, it can be used to treat deep tumor such as breast cancer because the light source is attached to the photosensitizers and are delivered to the tumor cells all together. This new modality is refereed as Nanoparticle Self-Lighting Photodynamic Therapy (NSLPDT).
Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.